TrIM25: A Zinc Finger Protein-147 as a Drug Target and Biomarker

Target Name: TRIM25

NCBI ID: G7706

TRIM25

TrIM25: A Zinc Finger Protein-147 as a Drug Target and Biomarker

Introduction

TrIM25, also known as Zinc Finger Protein-147, is a non-coding RNA molecule that plays a crucial role in various cellular processes. It is a protein-147 gene that encodes a protein involved in the regulation of microRNA (miRNA) levels. TrIM25 has been identified as a potential drug target and biomarker due to its unique structure and function.

Structure and Function

TrIM25 is a 21-kDa protein that contains a zinc finger domain, which is a common structural feature in proteins that bind small molecules with high affinity. The zinc finger domain is responsible for TrIM25's unique physical and functional properties, including its ability to interact with small molecules, such as drugs, and its capability to regulate the levels of miRNAs.

TrIM25 functions as a negative regulator of the microRNA pathway, which is a process that regulates the translation of genetic information from DNA to proteins. miRNAs are small non-coding RNAs that play a crucial role in post-transcriptional gene regulation by binding to specific target mRNAs. They act as scaffolds to recruit chromatin-remodeling enzymes to specific locations on the genome, where they can then target specific mRNAs for degradation or translation.

In cancer, miRNA levels are often disrupted, leading to the development of various diseases, including cancer. Therefore, targeting TrIM25 as a drug target could potentially lead to the development of effective therapies for various diseases.

Drug Sensitivity and Toxicity

TrIM25 has been demonstrated to be a drug-sensitive protein, which means that it can be targeted by small molecules, such as drugs, to induce various cellular responses. Several studies have shown that TrIM25 can be inhibited by small molecules, such as taxanes, which are commonly used in cancer treatment.

In addition, TrIM25 has also been shown to be sensitive to psychological stress, which can be an underlying factor in various diseases, including cancer. This suggests that TrIM25 could be a promising biomarker for various diseases, including cancer.

Pathway and Therapeutic Potential

TrIM25 has been shown to play a crucial role in the regulation of miRNA levels, which are often disrupted in cancer. Therefore, targeting TrIM25 as a drug target could potentially lead to the development of effective therapies for various diseases, including cancer.

One therapeutic potential approach for TrIM25-related diseases is to inhibit TrIM25 activity by small molecules, such as drugs. This could be achieved by targeting specific TrIM25 residues or by inhibiting the activity of TrIM25-interactive proteins.

Another potential approach for TrIM25-related diseases is to enhance TrIM25 activity by increasing the levels of TrIM25 in the body. This could be achieved by delivering TrIM25-containing drugs directly to cancer cells or by using TrIM25-activating agents to increase TrIM25 levels in cancer cells.

Conclusion

TrIM25 is a unique protein that has been identified as a potential drug target and biomarker due to its unique structure and function. Its ability to interact with small molecules and its role in the regulation of miRNA levels make it an attractive target for drug development.

In conclusion, TrIM25 is a promising protein for the development of various diseases, including cancer. Further research is needed to fully understand TrIM25's role in the regulation of miRNA levels and its potential as a drug target.

Protein Name: Tripartite Motif Containing 25

Functions: Functions as a ubiquitin E3 ligase and as an ISG15 E3 ligase (PubMed:16352599). Involved in innate immune defense against viruses by mediating ubiquitination of RIGI and IFIH1 (PubMed:17392790, PubMed:30193849, PubMed:33849980). Mediates 'Lys-63'-linked polyubiquitination of the RIGI N-terminal CARD-like region and may play a role in signal transduction that leads to the production of interferons in response to viral infection (PubMed:17392790, PubMed:23950712). Mediates 'Lys-63'-linked polyubiquitination of IFIH1 (PubMed:30193849). Promotes ISGylation of 14-3-3 sigma (SFN), an adapter protein implicated in the regulation of a large spectrum signaling pathway (PubMed:16352599, PubMed:17069755). Mediates estrogen action in various target organs (PubMed:22452784). Mediates the ubiquitination and subsequent proteasomal degradation of ZFHX3 (PubMed:22452784). Plays a role in promoting the restart of stalled replication forks via interaction with the KHDC3L-OOEP scaffold and subsequent ubiquitination of BLM, resulting in the recruitment and retainment of BLM at DNA replication forks (By similarity). Plays an essential role in the antiviral activity of ZAP/ZC3HAV1; an antiviral protein which inhibits the replication of certain viruses. Mechanistically, mediates 'Lys-63'-linked polyubiquitination of ZAP/ZC3HAV1 that is required for its optimal binding to target mRNA (PubMed:28202764, PubMed:28060952). Mediates also the ubiquitination of various substrates implicated in stress granule formation, nonsense-mediated mRNA decay, nucleoside synthesis and mRNA translation and stability (PubMed:36067236)

The "TRIM25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets